From molecular pathways to ASD therapy: Insights from syndromic forms of autism

Laura Nicholls, Radhika Ramadas, Irina Voineagu*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Citation (Scopus)

Abstract

Autism spectrum disorders (ASD) are highly heritable, yet genetically and clinically very heterogeneous. Currently, ASD treatment relies heavily on early behavioural intervention, which is partially effective but not curative, and specific pharmacological therapy for ASD is not yet available. Syndromic forms of ASD are genetic syndromes with a high incidence of autistic symptoms, which offer a unique opportunity for understanding the neurobiological mechanisms of ASD. Here we discuss the current progress in characterizing the molecular and neurobiological mechanisms underlying fragile X syndrome, Rett syndrome and tuberous sclerosis, as well as novel therapies developed for these syndromic forms of ASD. We further review recent evidence for common mechanisms underpinning syndromic and idiopathic ASD, and discuss the possibility of employing pharmacological agents developed for syndromic ASD to effectively treat idiopathic ASD.

Original languageEnglish
Title of host publicationFrontiers in Autism Research: New Horizons for Diagnosis and Treatment
PublisherWorld Scientific Publishing
Pages23-46
Number of pages24
ISBN (Electronic)9789814602167
ISBN (Print)9789814602150
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Autism genetics
  • Fragile X syndrome
  • Rett syndrome
  • Syndromic autism
  • Tuberous sclerosis

Fingerprint Dive into the research topics of 'From molecular pathways to ASD therapy: Insights from syndromic forms of autism'. Together they form a unique fingerprint.

Cite this